Lv et al. found that MEG3 inhibits migration and invasion of NSCLC cells and enhances PTEN expression via the PI3K/AKT signaling pathway, suggesting its potential as a novel therapeutic target for NSCLC64. Here, PTEN is linked to non-small cell lung carcinoma.